Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 21;44(20):1834-1836.
doi: 10.1093/eurheartj/ehac708.

JCAD: a new GWAS target to reduce residual cardiovascular risk?

Tomasz J Guzik  1   2 , Keith M Channon  3
Affiliations
Editorial

JCAD: a new GWAS target to reduce residual cardiovascular risk?

Tomasz J Guzik et al. Eur Heart J. .

Abstract

Divergent spectrum of the mechanisms of residual cardiovascular risk linked to JCAD that could be therapeutically targeted in the future.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Graphical Abstract
Graphical Abstract
Divergent spectrum of the mechanisms of residual cardiovascular risk linked to JCAD that could be therapeutically targeted in the future.
See this image and copyright information in PMC

Comment on

  • JCAD promotes arterial thrombosis through PI3K/Akt modulation: a translational study.
    Liberale L, Puspitasari YM, Ministrini S, Akhmedov A, Kraler S, Bonetti NR, Beer G, Vukolic A, Bongiovanni D, Han J, Kirmes K, Bernlochner I, Pelisek J, Beer JH, Jin ZG, Pedicino D, Liuzzo G, Stellos K, Montecucco F, Crea F, Lüscher TF, Camici GG. Liberale L, et al. Eur Heart J. 2023 May 21;44(20):1818-1833. doi: 10.1093/eurheartj/ehac641. Eur Heart J. 2023. PMID: 36469488 Free PMC article.

References

    1. Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem 2021;67:143–153. 10.1093/clinchem/hvaa252 - DOI - PMC - PubMed
    1. Fiolet ATL, Thompson PL, Mosterd A. Colchicine in coronary disease: another renaissance of an ancient drug. Cardiovasc Res 2021;117:e4–e6. 10.1093/cvr/cvaa342 - DOI - PubMed
    1. Liberale L, Montecucco F, Schwarz L, Luscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res 2021;117:411–422. 10.1093/cvr/cvaa211 - DOI - PubMed
    1. Murray EC, Nosalski R, MacRitchie N, Tomaszewski M, Maffia P, Harrison DG, et al. . Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovasc Res 2021;117:2589–2609. 10.1093/cvr/cvab330 - DOI - PMC - PubMed
    1. Erdmann J, Willenborg C, Nahrstaedt J, Preuss M, Konig IR, Baumert J, et al. . Genome-wide association study identifies a new locus for coronary artery disease on chromosome 10p11.23. Eur Heart J 2011;32:158–168. 10.1093/eurheartj/ehq405 - DOI - PubMed

Substances